{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T19:22:32Z","timestamp":1768418552496,"version":"3.49.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen","doi-asserted-by":"publisher","award":["AR-BGT-11742"],"award-info":[{"award-number":["AR-BGT-11742"]}],"id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s10072-024-07712-4","type":"journal-article","created":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T02:01:32Z","timestamp":1722391292000},"page":"5833-5840","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical effectiveness of dimethyl fumarate in multiple sclerosis patients from Argentina"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7435-5726","authenticated-orcid":false,"given":"Edgar","family":"Carnero Contentti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ricardo","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berenice","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Burgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dar\u00edo","family":"Tavolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgardo","family":"Cristiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Patrucco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Tkachuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina","family":"Mainella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisella","family":"Zanga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felisa","family":"Leguizam\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geraldine","family":"Luetic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emanuel","family":"Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"Tizio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Alonso Serena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Ignacio","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"7712_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.msard.2016.07.007","volume":"9","author":"E Cristiano","year":"2016","unstructured":"Cristiano E, Patrucco L, Miguez J et al (2016) Increasing prevalence of multiple sclerosis in Buenos Aires, Argentina. Mult Scler Relat Disord 9:91\u201394","journal-title":"Mult Scler Relat Disord"},{"key":"7712_CR2","doi-asserted-by":"publisher","first-page":"102006","DOI":"10.1016\/j.msard.2020.102006","volume":"41","author":"G Luetic","year":"2020","unstructured":"Luetic G, Menichini ML (2020) Multiple sclerosis prevalence in Santa Fe province, Argentina. Mult Scler Relat Disord 41:102006","journal-title":"Mult Scler Relat Disord"},{"key":"7712_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.msard.2018.07.033","volume":"25","author":"S Mellinger","year":"2018","unstructured":"Mellinger S, Dias D, Flores N, Palavecino A, Vigo G, Burgos D, Tomas F, Rollan I, Herrera G, Floridia J, Furlan C, Frissia F, Aleman A, Perez Fr\u00edas J, Casali J, Burgos M (2018) Multiple sclerosis prevalence in Salta City, Argentina. Mult Scler Relat Disord 25:212\u2013215","journal-title":"Mult Scler Relat Disord"},{"key":"7712_CR4","first-page":"205521731771505","volume":"3","author":"E Cristiano","year":"2017","unstructured":"Cristiano E, Rojas JI (2017) Multiple sclerosis epidemiology in Latin America: an updated survey. Mult Scler J Exp Transl Clin 3:2055217317715050","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"7712_CR5","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler 26:1816\u20131821","journal-title":"Mult Scler"},{"key":"7712_CR6","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. N Engl J Med 378:169\u2013180","journal-title":"N Engl J Med"},{"key":"7712_CR7","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1016\/S0140-6736(16)32388-1","volume":"389","author":"G Comi","year":"2017","unstructured":"Comi G, Radaelli M, Soelberg Sorensen P (2017) Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet 389:1347\u20131356","journal-title":"Lancet"},{"key":"7712_CR8","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1001\/jamaneurol.2019.0330","volume":"76","author":"O Beiki","year":"2019","unstructured":"Beiki O, Frumento P, Bottai M, Manouchehrinia A, Hillert J (2019) Changes in the risk of reaching multiple sclerosis disability milestones in recent decades: a Nationwide Population-based Cohort Study in Sweden. JAMA Neurol 76:665\u2013671","journal-title":"JAMA Neurol"},{"key":"7712_CR9","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/1352458518807082","volume":"25","author":"P Soelberg Sorensen","year":"2019","unstructured":"Soelberg Sorensen P, Giovannoni G, Montalban X, Thalheim C, Zaratin P, Comi G (2019) The multiple sclerosis care unit. Mult Scler 25:627\u2013636","journal-title":"Mult Scler"},{"key":"7712_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/S1474-4422(20)30067-3","volume":"19","author":"A He","year":"2020","unstructured":"He A, Merkel B, Brown JWL et al (2020) Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurol 19:307\u2013316","journal-title":"Lancet Neurol"},{"key":"7712_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fneur.2018.00005","volume":"9","author":"EA Mills","year":"2018","unstructured":"Mills EA, Ogrodnik MA, Plave A, Mao-Draayer Y (2018) Emerging understanding of the mechanism of action for Dimethyl Fumarate in the treatment of multiple sclerosis. Front Neurol 9:5","journal-title":"Front Neurol"},{"key":"7712_CR12","doi-asserted-by":"publisher","first-page":"102664","DOI":"10.1016\/j.msard.2020.102664","volume":"47","author":"R Alonso","year":"2021","unstructured":"Alonso R, Garcea O, Eizaguirre MB et al (2021) Usage trend of oral drugs for multiple sclerosis patients in Argentina. Mult Scler Relat Disord 47:102664","journal-title":"Mult Scler Relat Disord"},{"key":"7712_CR13","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL et al (2012) Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 367:1098\u20131107","journal-title":"N Engl J Med"},{"key":"7712_CR14","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1056\/NEJMoa1206328","volume":"367","author":"RJ Fox","year":"2012","unstructured":"Fox RJ, Miller DH, Phillips JT et al (2012) Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 367:1087\u20131097","journal-title":"N Engl J Med"},{"key":"7712_CR15","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1177\/1352458517709956","volume":"24","author":"K Smoot","year":"2018","unstructured":"Smoot K, Spinelli KJ, Stuchiner T et al (2018) Three-year clinical outcomes of relapsing multiple sclerosis patients treated with dimethyl fumarate in a United States community health center. Mult Scler 24:942\u2013950","journal-title":"Mult Scler"},{"key":"7712_CR16","doi-asserted-by":"publisher","first-page":"138","DOI":"10.7224\/1537-2073.2015-020","volume":"18","author":"J Calkwood","year":"2016","unstructured":"Calkwood J, Vollmer T, Fox RJ et al (2016) Safety and Tolerability of delayed-release Dimethyl Fumarate administered with Interferon Beta or Glatiramer acetate in relapsing-remitting multiple sclerosis. Int J MS Care 18:138\u2013146","journal-title":"Int J MS Care"},{"key":"7712_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17:162\u2013173","journal-title":"Lancet Neurol"},{"key":"7712_CR18","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","volume":"391","author":"L Kappos","year":"2018","unstructured":"Kappos L, Bar-Or A, Cree BAC et al (2018) Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 391:1263\u20131273","journal-title":"Lancet"},{"key":"7712_CR19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/00005650-198601000-00007","volume":"24","author":"DE Morisky","year":"1986","unstructured":"Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24:67\u201374","journal-title":"Med Care"},{"key":"7712_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1191\/1352458503ms902oa","volume":"9","author":"RH Benedict","year":"2003","unstructured":"Benedict RH, Fishman I, McClellan MM, Bakshi R, Weinstock-Guttman B (2003) Validity of the Beck Depression inventory-fast screen in multiple sclerosis. Mult Scler 9:393\u2013396","journal-title":"Mult Scler"},{"key":"7712_CR21","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1001\/archneur.1989.00520460115022","volume":"46","author":"LB Krupp","year":"1989","unstructured":"Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD (1989) The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 46:1121\u20131123","journal-title":"Arch Neurol"},{"key":"7712_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/1471-2377-11-127","volume":"11","author":"O Fernandez","year":"2011","unstructured":"Fernandez O, Fernandez V, Baumstarck-Barrau K et al (2011) Validation of the Spanish version of the multiple sclerosis International Quality of Life (Musiqol) questionnaire. BMC Neurol 11:127","journal-title":"BMC Neurol"},{"key":"7712_CR23","doi-asserted-by":"publisher","first-page":"729","DOI":"10.3389\/fneur.2017.00729","volume":"8","author":"MC Ysrraelit","year":"2017","unstructured":"Ysrraelit MC, Fiol MP, Gaitan MI, Correale J (2017) Quality of Life Assessment in multiple sclerosis: different perception between patients and neurologists. Front Neurol 8:729","journal-title":"Front Neurol"},{"key":"7712_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12883-019-1441-0","volume":"19","author":"MC Ysrraelit","year":"2019","unstructured":"Ysrraelit MC, Fiol MP, Pena FV et al (2019) Adaptation and validation of a Spanish version of the treatment burden questionnaire in patients with multiple sclerosis. BMC Neurol 19:209","journal-title":"BMC Neurol"},{"key":"7712_CR25","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1007\/s00415-020-09848-7","volume":"267","author":"J Sabin","year":"2020","unstructured":"Sabin J, Urtiaga S, Pilo B et al (2020) Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population. J Neurol 267:2362\u20132371","journal-title":"J Neurol"},{"key":"7712_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s40120-017-0064-x","volume":"6","author":"A Boster","year":"2017","unstructured":"Boster A, Nicholas J, Wu N et al (2017) Comparative Effectiveness Research of Disease-Modifying therapies for the management of multiple sclerosis: analysis of a large Health Insurance Claims Database. Neurol Ther 6:91\u2013102","journal-title":"Neurol Ther"},{"key":"7712_CR27","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1007\/s00415-018-9083-5","volume":"265","author":"S Braune","year":"2018","unstructured":"Braune S, Grimm S, van Hovell P et al (2018) Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol 265:2980\u20132992","journal-title":"J Neurol"},{"key":"7712_CR28","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/PPA.S284425","volume":"15","author":"A Rodriguez-Regal","year":"2021","unstructured":"Rodriguez-Regal A, Ramos-Rua L, Anibarro-Garcia L, Lopez Real AM, Amigo-Jorrin MDC (2021) Effectiveness of Dimethyl Fumarate in Real-World Clinical Practice and Strategy to minimize adverse effects and Use of Healthcare resources. Patient Prefer Adherence 15:149\u2013158","journal-title":"Patient Prefer Adherence"},{"key":"7712_CR29","doi-asserted-by":"publisher","first-page":"679355","DOI":"10.3389\/fneur.2021.679355","volume":"12","author":"L Lorefice","year":"2021","unstructured":"Lorefice L, Casaglia E, Fronza M et al (2021) The Dimethyl Fumarate experience: a handy drug with Broad Clinical Utility. Front Neurol 12:679355","journal-title":"Front Neurol"},{"key":"7712_CR30","doi-asserted-by":"publisher","first-page":"103038","DOI":"10.1016\/j.msard.2021.103038","volume":"53","author":"JI Rojas","year":"2021","unstructured":"Rojas JI, Carnero Contentti E, Abad P et al (2021) Research priorities in multiple sclerosis in Latin America: a multi-stakeholder call to action to improve patients care: research priorities in MS in LATAM. Mult Scler Relat Disord 53:103038","journal-title":"Mult Scler Relat Disord"},{"key":"7712_CR31","doi-asserted-by":"publisher","first-page":"e014433","DOI":"10.1136\/bmjopen-2016-014433","volume":"7","author":"R Arroyo","year":"2017","unstructured":"Arroyo R, Sempere AP, Ruiz-Beato E et al (2017) Conjoint analysis to understand preferences of patients with multiple sclerosis for disease-modifying therapy attributes in Spain: a cross-sectional observational study. BMJ Open 7:e014433","journal-title":"BMJ Open"},{"key":"7712_CR32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2147\/PROM.S168095","volume":"10","author":"O Ozel","year":"2019","unstructured":"Ozel O, Vaughn CB, Eckert SP, Jakimovski D, Lizarraga AA, Weinstock-Guttman B (2019) Dimethyl Fumarate in the treatment of relapsing-remitting multiple sclerosis: patient reported outcomes and perspectives. Patient Relat Outcome Meas 10:373\u2013384","journal-title":"Patient Relat Outcome Meas"},{"key":"7712_CR33","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1177\/1352458516649037","volume":"23","author":"R Gold","year":"2017","unstructured":"Gold R, Arnold DL, Bar-Or A et al (2017) Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler 23:253\u2013265","journal-title":"Mult Scler"},{"key":"7712_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1177\/13524585211037909","volume":"28","author":"R Gold","year":"2022","unstructured":"Gold R, Arnold DL, Bar-Or A et al (2022) Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results. Mult Scler 28:801\u2013816","journal-title":"Mult Scler"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07712-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07712-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07712-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T10:10:33Z","timestamp":1731319833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07712-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":34,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["7712"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07712-4","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,31]]},"assertion":[{"value":"17 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the ethics committee of each participating center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A written or verbal informed consent for the use of the anonymized data for research objectives was obtained from all participants before data collection.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Edgar Carnero Contentti has received reimbursement for developing educational presentations, educational and research grants, consultation fees and travel stipends from Bayer Pharmaceuticals Corp., Merck, Roche, Novartis, Raffo, Amgen, TEVA, Biogen, Genzyme Corp, Biosidus, AstraZeneca, LACTRIMS, Harvard Medical School (Postgraduate Medical Education), The Guthy-Jackson Charitable Foundation and The Sumaira Foundation. Ricardo Alonso has received reimbursement for research grants and travel stipends from Merck, Biogen and Genzyme. Marcos Burgos has received reimbursement for developing educational presentations, consultations fees, clinical trials fees and travel stipends from Biogen, Genzyme, Merck, Novartis, Teva, Tuteur. Liliana Patrucco has received reimbursement for developing educational presentations, educational and research grants, consultations fees and travel stipends from Biogen, Genzyme, Merck, Novartis. Dar\u00edo Tavolini has received reimbursement for developing educational presentations, educational and research grants, consultations fees and travel stipends from Biogen, Genzyme, Merck, Novartis. Edgardo Cristiano has received reimbursement for developing educational presentations and travel\/accommodations stipends from Merck-Serono Argentina, Biogen-Idec Argentina, Genzyme Argentina, Bayer Inc., Novartis Argentina and TEVA-Tuteur Argentina. Juan I. Rojas has received reimbursement for developing educational presentations, educational and research grants, consultations fees and travel stipends from Biogen, Genzyme, Merck, Novartis, Roche and MSIF. Berenice Silva has received reimbursement for developing educational presentations, educational and research grants, consultation fees and travel stipends from Biogen, Genzyme, Merck, Novartis. Pablo Lopez has received reimbursement for research grants and travel stipends from Merck, Biogen and Genzyme. Ver\u00f3nica Tkachuk has received reimbursement for developing educational presentations, consultations fees, clinical trials fees and travel stipends from Biogen, Genzyme, Merck, Novartis, Teva, Tuteur. Carolina Mainella has received reimbursement for developing educational presentations, educational and research grants, consultations fees and travel stipends from Biogen and Merck. Geraldine Luetic has received reimbursement for developing educational presentations, educational and research grants, consultations fees and travel stipends from Biogen, Genzyme, Merck, Novartis. Emanuel Silva, Felisa Leguizamon, Santiago Tizio, Marina Alonso Serena has nothing disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}